Claire Petry

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study

Christophe Schmitt, Joanne I. Adamkewicz, Jin Xu et al. · Thrombosis and Haemostasis · 2020 · 91 citations · Full text

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

Ekaterina Gibiansky, Claire Petry, François Mercier et al. · British Journal of Clinical Pharmacology · 2020 · 77 citations · Full text

Disease Progression, Neurological Disorder, Immunodeficiencies +21

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Martin S. Weber et al. · Neurology Neuroimmunology & Neuroinflammation · 2023 · 57 citations · Full text

Low immunogenicity of emicizumab in persons with haemophilia A

Christophe Schmitt, Thomas Emrich, Sammy Chebon et al. · Haemophilia · 2021 · 54 citations · Full text

Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A

Sylvie Retout, Christophe Schmitt, Claire Petry et al. · Clinical Pharmacokinetics · 2020 · 36 citations · Full text